Neutralizing antibodies (NAbs) are a major hurdle to the successful use of biologics in clinical practice. The impact of NAbs is obvious in biologic systems with no redundancy. NAbs induced in response to treatment with recombinant erythropoietin or thrombopoietin cause life-threatening complications of pure red cell aplasia and thrombocytopenia as a direct result of inhibiting the activity of the endogenous hormones. For the type 1 interferons (␣ and ␤), NAbs have not yet been shown to have untoward biologic effects. This may relate to the fact that IFN␣ and IFN␤ have overlapping biologic activities or that they are produced locally as autocrine or paracrine mediators and are therefore less likely to be exposed to NAbs. In comparison, the evidence that NAbs interfere with the therapeutic effect of type 1 interferons is much clearer. In subjects with multiple sclerosis (MS), NAbs inhibit the induction of IFN␤-specific gene products and lessen the benefit of IFN␤ on both MRI activity and relapse rate. Furthermore, three articles in this issue of Neurology show that NAbs 1,2 impact negatively on disease progression and are likely to persist. 3 NAbs do not appear until 6 to 24 months after IFN␤ is initiated and do not have consistently measurable effects in trials of less than 2 years' duration. In the pivotal IFN␤-1b study (Betaseron/Betaferon), the clinical impact of NAbs on MS relapse rate only became apparent after 18 months of therapy. 4 In the subcutaneous IFN␤-1a PRISMS study (Rebif) there were no reported differences in the clinical and MRI endpoints between NAbϩ and NAbϪ patients at 2 years. 5 However, in the 4-year extension phase of PRISMS, the relapse rate was 60% greater (0.81 vs 0.50, p ϭ 0.002), the median number of T2 active lesions was five times greater (1.4 vs 0.3, p Ͻ 0.01), and the median change from baseline in the MRI burden of disease was three times greater (ϩ17.6% vs -8.5%, p Ͻ 0.001) in NAbϩ compared with NAbϪ subjects. 6 In the pivotal once-weekly IM IFN␤-1a (Avonex) trial, which was terminated early, a strong trend toward reduced treatment benefit on MRI, but not clinical disease activity, was seen in NAbϩ patients. 7 Data on the impact of NAbs on MS disease progression have been less clear. In fact, none of the phase III IFN␤ trials was powered to detect an effect of NAbs on disease progression. Despite this, data have now demonstrated an impact of NAbs on disease progression. In a recently published open-label study of 78 IFN␤-treated MS subjects followed for a median of 3 years, a higher percentage of NAbϩ patients vs NAbϪ patients had worsening of Expanded Disability Status Scale (EDSS) scores during the period of follow-up (p ϭ 0.013). 8 Similarly, in a second open-label study of 65 subjects followed for up to 4 years, the mean EDSS score increased from 2.2 Ϯ 0.8 at baseline to 3.6 Ϯ 1.2 at year 2 in the 10 subjects with high-titer NAbs compared with NAbϪ subjects in whom there was no significant change in their EDSS scores (p Ͻ 0.01).
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A re-analysis of the impact of NAbs in the PRISMS study, published in this issue of the Journal, 1 shows that over the entire 4 years of study, relapse and disability measures were similar between NAbϩ and NAbϪ patients. However, once NAbs developed, significant differences were noted between NAbϩ and NAbϪ groups on MRI, relapse, and disability outcome measures. As expected, the impact on disability was less predictable than on the other outcomes. In fact, it was only significant in the "interval-positive analysis," in which subjects provide data to both the NAbϩ and NAb-groups depending on their status at the time data were collected. Using this method, the difference between NAbϩ and NAb-groups in the rate of confirmed 1-point EDSS change was significant over the 4 years of the study (NAbϩ/NAbϪ rate ratio ϭ 1.50, 95% CI 1.03-2.17, p ϭ 0.03). Also in this issue, Kappos et al. 2 report that in the European IFN␤-1a (Avonex) dose-comparison study in which patients were randomized to treatment with IFN␤-1a 30-g or 60-g IM once weekly for up to 4 years, NAbϩ subjects had a higher rate of mean change or worsening in the EDSS score from baseline to month 48 compared with NAbϪ subjects (p ϭ 0.01).
Of interest in both the PRISMS-4 1 and pivotal IFN␤-1b 4 studies, subjects who were destined to develop NAbs had a greater reduction in relapse rate in the first 6 months of therapy compared with subjects who did not go on to develop NAbs. This not only dilutes the negative impact of NAbs on relapse rates when using data averaged across the whole study period, but suggests a difference in the biologic response of these subjects to IFN␤ therapy. This observation deserves further study. At present it is not possible to predict which subjects will develop NAbs. The majority of subjects who develop binding antibodies early after initiating IFN␤ therapy will go on to develop NAbs. It may therefore be possible to treat binding-positive patients early, using various strategies, to prevent NAbϩ seroconversion. 10 Approximately 30% of NAbϩ subjects become NAbϪ spontaneously over a period of several years; subjects treated with IFN␤-1b 11 and with low NAb titers (Ͻ75-100 NU) are more likely to revert to NAbϪ. 12, 13 Additional data on reversion rates are presented in this issue from the large Danish population-based study. 3 Of 455 subjects with MS treated for at least 24 months on IFN␤, 52% were classified as persistently NAbϪ, 41% as persistently NAb-positive (at least two consecutive positive samples 6 months apart), and the remaining 7% fluctuated between being NAbϩ and NAbϪ. Subjects who remained NAbϪ after 24 months of therapy rarely developed NAbs. The majority of subjects, who had been NAbϩ from 12 through 30 months after the start of IFN␤ therapy, remained NAbϩ. Reversion to NAbϪ was more common with IFN␤-1b than IFN␤-1a; 52% of NAbϩ subjects on IFN␤-1b reverted to NAbϪ after 36 months compared with only 19% of subjects receiving IFN␤-1a. The finding that reversion to being NAbϪ is more frequent with IFN␤-1b than with IFN␤-1a may be because tolerance is more likely to occur with ongoing administration of larger protein loads during IFN␤-1b treatment. The ongoing trial studying the standard dose and double-dose IFN␤-1b (BEYOND) will help elucidate whether this strategy could help reduce further the occurrence and persistence of NAbs.
Incorporating NAbs and NAb testing into clinical practice. Despite the increasing evidence that NAbs abrogate or reduce the clinical efficacy of IFN␤ on MRI outcomes, on relapse rate, and now on disability progression, NAb testing has not been part of routine clinical practice. Avoiding NAbs by opting for a low immunogenic preparation from the outset, e.g., IM IFN␤-1a, is a reasonable strategy. However, this strategy may compromise clinical efficacy: weekly IM IFN␤-1a is less efficacious in short-term studies than both IFN␤-1a 44 g SC three times weekly 14 and IFN␤-1b 250 g SC every other day. 15 The superior efficacy of high-frequency IFN␤ preparations needs to be weighed against the greater risk of developing NAbs with these preparations.
Once a person with MS is in treatment, it seems reasonable to screen for NAbs at 12 and 24 months or at the time of a relapse. If a subject has not seroconverted after 24 months of therapy, he or she is unlikely to do so; therefore, further routine testing is not recommended.
At present there is little evidence to guide clinicians on how to manage persistently NAbϩ subjects who are doing well clinically. Ideally, these subjects should be studied to determine how to manage them appropriately. Currently, the NAb test should be viewed as predictive; NAbϩ subjects are more likely to fail IFN␤ therapy in the future compared with NAbϪ subjects; the odds of having a relapse in a NAbϩ period compared with a NAbϪ period is between 1.51 and 1.58 (p Ͻ 0.03), and the time to first relapse is prolonged on average by 244 days in subjects who are NAbϪ at 12 months after the start of IFN␤ treatment compared with those who are NAbϩ (p ϭ 0.009).
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It has been argued that is unnecessary to test for NAbs in subjects who have had a relapse as clinicians would be inclined to stop or switch treatment in these patients regardless of their NAb status. As IFN␤ is only partially effective, the majority of patients would be expected to have a breakthrough in disease activity at some stage, but this does not necessarily imply the subject is an IFN␤ nonresponder. However, if this subject were persistently NAbϩ, one would classify him or her as being a nonresponder and would have a good reason to switch therapy. Some have proposed switching to a less immunogenic IFN␤ preparation. In one report, switching NAbϩ IFN␤-1b-treated patients to the less immunogenic IM IFN␤-1a resulted in 53% reverting to NAbϪ after 1 year and 75% reverting to NAbϪ after 2 years. 16 Randomized clinical studies are currently being undertaken to evaluate this strategy. As NAbs to IFN␤-1b and IFN␤-1a are cross-reactive, we do not recommend switching within the IFN␤ class at present.
In conclusion, it is well established that NAbs reduce the biologic and clinical efficacy of IFN␤. The efficacy of IFN␤ and hence the cost-effectiveness of treatment will be improved if the development of NAbs can be prevented or reversed. Subjects with MS who develop NAbs are likely to become IFN␤ nonresponders. They are by definition at higher risk of having relapses in the future (if they have not already had them) and can now be considered to be at increased risk of disease progression. The rationale for incorporating NAb testing into clinical practice and for doing appropriately powered switching studies to establish how to manage NAbϩ subjects who are "doing well" on IFN␤ is compelling. In addition, strategies to prevent or reverse the development of NAbs need to be explored. The overall efficacy of IFN␤ therapy as a class of MS diseasemodifying therapies can be improved if the problem of NAbs can be overcome.
